Ocuphire Pharma
patient population subject disposition | Ocuphire Pharma
Company
Deck Type
Deck date
June 2021
Slide
11 of 33
Related slides by other companies
Equillium
Investor Presentation
December 2023
clinically validated in severe dermatological disease | Equillium
Neumora Therapeutics
IPO
September 2023
phase efficacy population patient demographics and characteristics similar across treatment groups | Neumora Therapeutics
Immix Biopharma
Investor Presentation
March 2024
sizable relapsed refractory amyloidosis patient population immix | Immix Biopharma
Dynacure
IPO
July 2021
our population is of patients in the | Dynacure
Other recent decks by Ocuphire Pharma
See all presentations (10 decks)
Investor Presentation
November 2023
Investor Presentation
August 2023
Investor Presentation
May 2023
Results
January 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights